Apollo Medical Holdings, Inc. — Form 10-Q Summary
Issuer identity: The filing is by Apollo Medical Holdings, Inc., not under the name Astrana Health, Inc. It covers the three months ended June 30, 2014; following a fiscal-year-end change from January 31 to March 31, this represents the first quarter of the new fiscal year. Financial statements are unaudited.
Business context and reporting period
The company operated an integrated, physician-centric healthcare delivery system in California, serving Medicare, commercial, and Medi-Cal patients through physician groups, hospital services, clinics, and risk- and value-based arrangements. It reported results on a consolidated basis, including certain affiliated medical groups managed under long-term agreements.
Key financial metrics
| Metric | Three months ended June 30, 2014 | Prior-year period |
|---|---|---|
| Revenue | $4.09 million | $2.61 million |
| Cost of services | $3.26 million | $2.46 million |
| Gross profit / margin, calculated as revenue less cost of services | $0.83 million / 20.4% | $0.16 million / 6.0% |
| Operating loss / margin | $1.19 million / (29.0%) | $1.77 million / (67.7%) |
| Net loss | $1.51 million | $1.93 million |
| Net loss attributable to Apollo Medical Holdings, Inc. | $1.68 million | $1.93 million |
| Basic and diluted loss per share | $0.03 | $0.05 |
| Net cash used in operating activities | $1.10 million | Net cash provided of $0.16 million |
At June 30, 2014, cash and cash equivalents were $5.76 million and marketable securities were $0.41 million. Current assets were $7.84 million versus current liabilities of $3.15 million. Total liabilities were $11.80 million, including approximately $6.66 million of notes and line-of-credit balances and a $2.38 million warrant liability. Stockholders’ deficit was $2.99 million. The filing’s MD&A describes borrowings as approximately $6.7 million.
Material changes versus the prior comparable period
- Revenue increased 56.6%, principally from growth in Maverick Medical Group’s Medicare patient lives and clinic activity; the filing also identifies revenue from the AKM acquisition. Nonrenewal of certain hospitalist contracts reduced revenue.
- Operating loss narrowed by approximately $0.58 million. Management attributed the improvement mainly to a $1.43 million year-over-year decrease in stock-based compensation, partly offset by higher medical-service costs and legal and professional fees.
- Interest expense rose by approximately $0.12 million, primarily due to higher borrowings associated with the 2014 NNA financing.
- Operating cash flow shifted from $0.16 million provided to $1.10 million used. The filing notes that increased medical liabilities, including liabilities assumed in the AKM acquisition, contributed cash in working capital.
- Cash and cash equivalents declined from $6.83 million at March 31, 2014 to $5.76 million at June 30, 2014. The company also held $0.41 million of marketable securities at quarter-end.
Outlook, management commentary, risks, and unusual items
- Management said existing cash balances, together with operating cash flow, were expected to meet working-capital needs for the foreseeable future, while cautioning that future financing might not be available on acceptable terms or at all. No numerical earnings or revenue guidance was provided.
- The March 2014 NNA financing included a $7 million secured term loan, a $1 million revolving facility, a $2 million convertible-note commitment, and an equity investment. The revolving facility had no balance drawn at June 30. The $2 million convertible note was funded on July 30, 2014. The debt agreements contain covenants; the company reported compliance at June 30.
- In May, the company acquired AKM Medical Group, an IPA with more than 100 physicians and over 2,100 patients. The stated purchase consideration was $276,822, including a $136,822 holdback subject to specified adjustments and claims. The purchase-price allocation was preliminary and included a $216,565 bargain-purchase amount recorded as a reduction to goodwill pending reassessment.
- After quarter-end, an affiliate acquired a Los Angeles County medical group for $2 million cash, repayment of $362,646 of indebtedness, warrants for up to 1 million shares, and potential contingent cash consideration of up to $1 million. The company expected to consolidate the target under a management agreement.
- Three payors each represented 19.6%, 15.8%, and 15.3% of quarterly revenue. Two payors represented 21.4% and 9.5% of accounts receivable at quarter-end.
- Medical-liability estimates include incurred-but-not-reported claims and are subject to actuarial estimates and contract interpretation. The company also bears risk under full-risk capitation arrangements and disclosed a $20,000 per-member professional stop-loss, with none for institutional risk pools.
- Competitors’ claims alleging improper solicitation were moved from court proceedings to arbitration in August 2014. The company said it could not yet assess the likelihood or potential amount of loss; punitive damages previously sought in court are unavailable in arbitration.
- Management concluded disclosure controls and internal controls over financial reporting were ineffective at June 30, citing three material weaknesses: no written internal-control documentation, insufficient segregation of accounting duties, and inadequate review and supervision. Remediation was underway.
- The company reported cumulative losses and a full valuation allowance against deferred tax assets. Stock options, warrants, convertible securities, and future equity compensation may also create dilution.
Important facts for investors to verify
- Confirm issuer identity and period: the filing names Apollo Medical Holdings, Inc. and reports the quarter ended June 30, 2014; the fiscal-year change makes this its first quarter under a March 31 year-end.
- Review the quality and sustainability of revenue growth, including patient growth, acquisitions, payor concentration, and lost hospitalist contracts.
- Assess medical-liability reserve adequacy, full-risk exposure, and how the AKM holdback and preliminary bargain-purchase accounting were ultimately resolved.
- Evaluate liquidity and debt service against continuing operating cash outflows, loan covenants, the July convertible-note funding, and subsequent acquisition commitments.
- Track remediation of the three disclosed material weaknesses and developments in the arbitration and other medical-liability claims.